-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を804ドルから750ドルに引き下げました。これは、2027年のEPS予想PERが約19倍で、長期平均を下回る水準です。2026年のEPS予想を30.68ドルから29.29ドルに、2027年のEPS予想を36.68ドルから39.39ドルにそれぞれ修正しました。第1四半期の売上高が33%増、第2四半期のガイダンスも25%増と好調な伸びを示したことから、METAは広告プラットフォーム全体でAI投資を効果的に活用する方法を見出していると考えられます（バリュー最適化スイートの年間売上高は200億ドル以上）。しかしながら、経営陣が広告費の増加や新製品開発への意欲をどのように収益化していくのかについて、投資家に対して明確な説明ができなかったことは残念です。また、パーソナルAIエージェント、ビジネスAIサブスクリプション（METAは現在、週平均1,000万件のビジネスAI会話を実施）、MuseモデルへのAPIアクセスといった新たな収益源の可能性は、今後3～5年で広告以外の収益源を大幅に多様化させる可能性があります。株価は魅力的な2027年予想EPSの15～16倍で取引されており、METAが成長目標を達成し、広告プラットフォームの収益化を継続できれば、上昇余地があります。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
$FE
Sectors
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
$LW
Australia
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%
$AZN